ThromboGenics NV News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.05.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
05.05.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS (GlobeNewswire)
03.05.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
28.04.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS (GlobeNewswire)
27.04.23	Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC (GlobeNewswire)
24.04.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
14.04.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
07.04.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS (GlobeNewswire)
31.03.23	Oxurion Publishes 2022 Annual Report (GlobeNewswire)
31.03.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS (GlobeNewswire)
24.03.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA (GlobeNewswire)
21.03.23	Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL (GlobeNewswire)
14.03.23	Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes (GlobeNewswire)
09.03.23	Oxurion Receives Transparency Notification from Negma Group (GlobeNewswire)
02.03.23	Oxurion Receives Transparency Notification from Negma Group (GlobeNewswire)
02.03.23	Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To €20 Million in Funding (GlobeNewswire)
02.03.23	Funding Program between Oxurion and Negma Ends (GlobeNewswire)
24.02.23	Oxurion Receives Transparency Notifications from Negma Group (GlobeNewswire)
24.02.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
17.02.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
17.02.23	Oxurion Receives Transparency Notifications from Negma Group (GlobeNewswire)
10.02.23	Oxurion Receives Transparency Notifications (GlobeNewswire)
10.02.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
23.11.22	Oxurion Further Improves THR-149 Patent Position (GlobeNewswire)
18.11.22	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
18.11.22	Oxurion Announces Interim Analysis for KALAHARI Trial (GlobeNewswire)
17.11.22	Oxurion Receives Transparency Notifications Based on New Denominator (GlobeNewswire)
11.11.22	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
04.11.22	Oxurion Receives Transparency Notification from Fidelity Management & Research Company LLC (GlobeNewswire)
04.11.22	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
28.10.22	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
18.10.22	Oxurion To Participate in Upcoming Investor Conferences (GlobeNewswire)
30.09.22	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
12.09.22	Oxurion To Participate in Upcoming Scientific and Investor Conferences (GlobeNewswire)
07.09.22	Oxurion Publishes First Half 2022 Results (GlobeNewswire)
02.09.22	Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding (GlobeNewswire)
26.08.22	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
24.08.22	Oxurion To Present at Upcoming Scientific and Investor Conferences (GlobeNewswire)
29.07.22	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
11.07.22	Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences (GlobeNewswire)
30.06.22	Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds (GlobeNewswire)
13.06.22	Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting (GlobeNewswire)
07.06.22	Oxurion Announces Preclinical Presentation on THR-149 at KININ2022 (GlobeNewswire)
03.06.22	Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting (GlobeNewswire)
01.06.22	Oxurion to Participate in Upcoming Investor Conferences (GlobeNewswire)
31.05.22	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (GlobeNewswire)
25.05.22	Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022 (GlobeNewswire)
24.05.22	Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022 (GlobeNewswire)
09.05.22	Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) (GlobeNewswire)
11.04.22	Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ThromboGenics NV

Aktien Top/Flop

Meistgelesene Nachrichten